Results 201 to 210 of about 56,599 (248)

Psoriatic Arthritis: Therapeutic Advances and Novel Treatment Strategies-A Scoping Review. [PDF]

Life (Basel)
Athanassiou L, Kostoglou-Athanassiou I, Kaiafa G, Savopoulos C, Shoenfeld Y, Athanassiou P.   +5 more
europepmc   +1 more source

Evaluating the Safety and Effectiveness of Perispinal Etanercept for Post-Stroke Recovery: A Systematic Review. [PDF]

Cureus
Sanghi M, Khanijoun N, Hamza N.
europepmc   +1 more source

Beyond Monotherapy: Exploring the Efficacy and Safety of Dual Biologic Strategies in Rheumatic Diseases. [PDF]

Biologics
Hassan F, Jeries H, Daood R, Naffaa ME.
europepmc   +1 more source

Assessment of adalimumab used in a patient with hemorrhagic rheumatoid neutrophilic dermatosis. [PDF]

Postepy Dermatol Alergol
Wei T, Duan Z, Chen H, Xiang Z, Li CR.
europepmc   +1 more source

Rituximab for the treatment of membranous nephropathy in a patient with ankylosing spondylitis: a case report. [PDF]

Front Med (Lausanne)
Zhong R, Su L, Li H, Zhu H, Xiao Z.
europepmc   +1 more source

Optimising Therapeutic Intervals for Anti-TNF Biologics in Rheumatoid Arthritis: A Retrospective Real-World Study. [PDF]

Life (Basel)
Dodero-Anillo JM, Rosety-Rodriguez M, Pedrosa-Martinez MJ.   +2 more
europepmc   +1 more source

Long-term safety and efficacy in paediatric psoriasis: Remaining challenges. [PDF]

J Eur Acad Dermatol Venereol
Droitcourt C, Goaziou NL.
europepmc   +1 more source

Hepatic Vascular Involvement in Adenosine Deaminase 2 Deficiency (DADA2): Case Reports and Literature Review. [PDF]

Diagnostics (Basel)
Sparchez M, Damian L, Socaciu MA, Fufezan O, Sparchez Z.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Etanercept

Expert Opinion on Biological Therapy, 2008
In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease.
Erin, Ducharme, Jeffrey M, Weinberg
  +5 more sources

Etanercept: an introduction

Expert Review of Clinical Immunology, 2005
Etanercept is a member of a new generation of therapeutic agents referred to as biologics or targeted therapies, which have caused some enthusiasm in the field of autoimmune disorders in recent years. Most of these agents are inhibitors of tumor necrosis factor, a key cytokine in the chronic inflammatory process.
Mathias, Grunke, Joachim Robert, Kalden
openaire   +2 more sources